💊Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032 .
Overall response rate with Opdivo was 21%, and more than double with the Opdivo plus Yervoy combination (46%), in patients with high tumor mutation burden
Overall survival rate with Opdivo at one year was 35%, and nearly double with the Opdivo plus Yervoy combination (62%), in patients with high tumor mutation burden
First report of tumor mutation burden as a potential predictive biomarker for the combination of two I-O agents
BMS Newsroom